光量子加利培酮治疗首发精神分裂症

Light Quantum Therapy in Combination with Risperidone in The Treatment of Initial Schizophrenia

目的 :探索光量子治疗精神分裂症的辅助性作用。方法 :选择首次发病住院并符合CCMD 2 R标准的精神分裂症患者共 14 5例。随机分为AB 2组 ,均采用口服利培酮治疗 ,A组在服药后的第 2 8d辅以光量子治疗 10次。 2组治疗前后评定BPRS、TESS ,检查肝、肾功能及血、尿常规。按 4级标准评定疗效。结果 :A组BPRS降分较B组快 ,副反应较B组小 ,住院时间显著缩短。 2组总疗效差异无显著性。结论 :光量子可以作为精神分裂的辅助性治疗手段 ,可促进精神症状好转加快、住院时间缩短和减轻利培酮的副作用 。

Objective: To explore the accessory treatment of schizophrenia by light quantum. Methods: 145 cases of initial schizophrenia meeting the CCMD 2 R standard were randomly divided into two groups. Risperidone was orally administered in the two groups. In the group A, light quantum therapy was given once every day for 10 times at 28th day after administration. Before and after treatment, BPRS, TESS, liver and kidney function, and blood and urine routine were assessed according to 4 grade standard. Results: In the group A, the BPRS score was decreased more quickly than group B (only receiving Risperidone treatment), side reactions were milder than in thegroup B, and the hospitalization stay was significantly shortened. There was no significant difference in the total effectiveness between the two groups. Conclusion: Light quantum therapy can be used as an accessory treatment for schizophrenia, promote the recovery of the mental symptoms, shorten the hospitalization stay, alleviate the side reactions of Risperidone, but cann't improve the effectiveness for schizophrenia.